BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Singapore Halts Dosing of Two Flu Shots After 59 Deaths in South Korea

  South Korea, on the other hand, indicated they would continue their state-run vaccination program because they did not find a direct link between the deaths and the vaccinations.

  October 27, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Lone Star Bio

  Caris Life Sciences Secures $310 Million to Advance Precision Medicine Toolset

  Molecular science company Caris Life Sciences secured $310 million in growth capital that will be used to expand its presence in precision medicine in oncology.

  October 27, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  Kala Gets the Greenlight from FDA for Dry Eye Disease Treatment EYSUVIS

  EYSUVIS is the first FDA-approved ocular corticosteroid for the treatment of dry eye disease. Know more about how it got approval and the complete development timeline here.

  October 27, 2020

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  CAR T Therapy Helps Toddler Emerge Victorious Over Infant Leukemia

  Chasity’s story stands in hopeful defiance of a typically grim acute lymphocytic leukemia prognosis. In this case, CAR T cell therapy has proven to be a uniquely viable option.

  October 27, 2020

   · 

  3 min read

   · 

  Abbey Glasure
• 

  Drug Development

  Lilly and NIAID Halt COVID-19 Antibody Trial in Hospitalized Patients

  Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”

  October 27, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Update – COVID-19 by the Numbers: Excess Deaths Remain High, but are Declining

  Excess mortality rates in the U.S. remain high, despite a steady decline since mid-December.

  October 27, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Deals

  Biopharma Money on the Move: October 21-27

  Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

  October 27, 2020

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Business

  CStone Enters $1 Billion Deal with EQRx to Advance Immunotherapy Agents

  The agreement provides exclusive rights to EQRx for CStone’s late-stage immuno-oncology anti-PD-L1 monoclonal antibody sugemalimab and anti-PD-1 CS1003.

  October 27, 2020

   · 

  3 min read

   · 

  Brandon May
• 

  Policy

  Biopharma Update on the Novel Coronavirus: October 27

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.

  October 27, 2020

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Deals

  Exact Sciences to Acquire Thrive in Deal Valued at $2.15 Billion

  The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval.

  October 27, 2020

   · 

  3 min read

   · 

  Krystle Vermes